Urothelial Cancers Phase 3 Trial KEYNOTE-045 and KEYNOTE-361 Efficacy and Safety Results Bladder 3 Mins Read8 Patrizia Giannatempo, MD, from the Fondazione IRCCS Istituto Nazionale dei Tumori, has conducted extensive research on the impact of histology…
Urothelial Carcinoma PROOF 302: A phase III trial of Infigratinib in FGFR3 alterations Bladder 3 Mins Read7 Petros Grivas, MD, PhD, an expert in urothelial carcinoma (UC) research at the University of Washington, has made significant contributions…
